Clinical data shows that tirzepatide takes time to reach full effectiveness , and the early weeks are about adjustment, not maximum results
Fatima Cody Stanford, MD, MPH, MPA, MBA, is an obesity medicine physician, scientist, and Associate Professor of Medicine and Pediatrics at Massachusetts General Hospital and Harvard Medical School
Some of the ongoing research directions include: Long-term safety and efficacy: As BPC-157 is a relatively new compound, long-term studies are needed to establish its safety and efficacy in various populations and for different indications
Semaglutide and Tirzepatide are proven to support steady, sustainable weight loss when coupled with exercise by enhancing your metabolism and effectively encouraging healthier eating habits